Credit Card Icon
Online bill pay
Calendar Icon
Book Now
Filed Paper Icon
patient portal
Doctor Icon
For Physicians
Phone Icon
(763) 416-7600

Understanding Choroidal Melanoma: Diagnosis, Treatment, and Care

Posted by: Northwest Eye in choroidal melanoma on August 27, 2025

Know where choroidal melanoma starts

Choroidal melanoma is a cancer that starts in pigmented cells in the choroid. The choroid is part of the uveal tract, which also includes the iris and ciliary body.

Because the tumor develops inside the eye, you may not see it or feel it as it begins. It is a primary tumor of the eye, rather than a cancer that started elsewhere and spread to the eye.

The condition is rare. Uveal melanoma occurs at about six cases per million person-years. These figures describe population-level occurrence, not your personal risk.

A dilated-pupil internal eye examination is central to diagnosis. One clinical review reported that this examination correctly diagnosed the tumor in more than 95% of cases, but that figure comes from a particular diagnostic setting and does not replace imaging or specialist judgment.

Imaging can reveal changes beneath the visible surface. One report described choriocapillaris compression and thinning in 100% of cases and optical choroidal shadowing in 100% of cases. Those percentages describe that report, not every tumor.

Understand what may raise risk

Uveal melanoma has no known single cause. Several features have been associated with higher risk, but having one of them does not diagnose a tumor.

Recognized risk factors include:

  • Light skin or light-colored eyes.
  • An inability to tan, freckles, or skin moles.
  • Nevi, which are pigmented growths, on the iris or in the choroid.
  • Ocular or oculodermal melanocytosis, conditions that increase pigment in or around the eye.
  • BAP1 tumor predisposition syndrome, an inherited condition linked with higher cancer risk.

Ultraviolet exposure has been considered a possible risk factor. Later studies have questioned that association because tumor cells show a very low mutation burden. The practical point is that ultraviolet exposure is not an established explanation for every case.

One systematic review reported that almost 50% of people with this disease develop metastases. This is a population finding, not a prediction about your situation.

A choroidal nevus is a benign pigmented growth, but some features make later growth more concerning. In one cited growth model, relative risk was 2.5 with one clinical risk factor, 3 with two risk factors, and 4 with three risk factors. Relative risk compares groups in that model; it does not predict what will happen to your eye.

A shaggy appearance of the photoreceptors over a tumor was reported in 49% of cases in one imaging report, especially in small tumors. That finding may help distinguish a malignant tumor from a benign nevus, but it is only one part of an examination.

Infographic chart showing relative risk for choroidal nevus growth in the cited model: 2.5 with one clinical risk factor, 3 with two risk factors, and 4 with three risk factors. Relative risk compares groups.
The cited model showed higher relative risk as clinical risk factors increased.

Notice changes even when there is no pain

This cancer may cause no symptoms early and may be found during a routine dilated eye examination. Lack of pain or clear vision changes does not show that a suspicious finding is harmless.

Possible symptoms include:

  • Vision loss or blurry vision.
  • Flashes of light.
  • Floaters, which are moving spots or shapes in your vision.
  • Worsening loss of part of your visual field.
  • Severe pain, although severe pain is unusual.

Severe pain is unusual, although a large tumor can occasionally cause it. Pain is therefore not a reliable way to judge whether an eye finding needs evaluation.

This tumor is the most common primary intraocular malignancy in adults and represents 80% of all uveal melanomas. That classification describes the type of tumor, not how common it is overall; the condition itself remains rare.

For tumors thicker than 3 mm, one review reported 95% accuracy for combined A- and B-scan ultrasound. The measurement applies to that tumor-thickness group and does not mean every suspicious eye finding has the same accuracy.

If a choroidal nevus has no listed risk features, one review recommends follow-up every six months during the first year and then once each year. With one or two features, that review recommends follow-up every four to six months. Your specialist sets the schedule for your finding.

Understand why a nevus may need monitoring

A choroidal nevus is a benign pigmented lesion, while the cancer described here is malignant. The tumor may develop from a preexisting melanocytic nevus, although it can also grow de novo, meaning it starts without a known earlier nevus.

Specialists assess a nevus by looking for growth and a group of structural or imaging features. Those features can include:

  • Thickness equal to or greater than 2 millimeters on ultrasound.
  • Fluid beneath the retina on optical coherence tomography, or OCT.
  • Vision symptoms or flashes of light.
  • Orange pigment on autofluorescence imaging.
  • A hollow appearance on ultrasound.
  • A diameter equal to or greater than 5 millimeters on eye photography.
  • A location within 3 millimeters of the optic disc.
  • An absent halo or absent drusen around the lesion.

These findings are clues, not a home diagnosis. Thickness over 2 mm, subretinal fluid, visual symptoms, orange pigment, a tumor near the optic disc, ultrasound hollowness, an absent halo, and absent drusen have all been associated with nevus growth or malignant transformation.

Echographic follow-up for at least 1.5 years may be needed to distinguish a suspicious nevus from a malignant tumor. A stable appearance over time can help the specialist, but the follow-up interval depends on the lesion’s features and your overall eye findings.

Start with a dilated eye examination

A dilated eye examination starts the evaluation of a suspected tumor. The clinician views the inside of your eye through a dilated pupil and considers your symptoms, photographs, and earlier examinations. One review reported more than 95% correct diagnosis from this type of examination, but reported accuracy depends on the clinical setting.

The evaluation may include:

  1. A specialist internal eye examination. Indirect ophthalmoscopy lets the clinician inspect the retina, choroid, optic disc, and nearby structures.
  2. A- and B-scan ultrasound. B-scan ultrasound can help establish a diagnosis, measure the tumor, check for extension outside the eye, follow a lesion during observation, and plan treatment.
  3. Optical coherence tomography. OCT can detect fluid beneath the retina before that fluid is visible during a regular fundus examination.
  4. Other imaging. Evaluation may include fluorescein angiography, transillumination, fundus photography, or autofluorescence imaging when those tests add useful information.

Echographic thickness of at least 2 mm and a largest basal diameter of at least 7 mm can help identify small tumors. These measurements support specialist interpretation; they do not establish a diagnosis by themselves.

One imaging report described subretinal fluid in 92% of cases. It also noted that OCT may find the fluid when clinical examination misses it. This percentage describes the reported group, not every tumor.

Fine-needle aspiration is more selective. Because it can cause significant harm, clinicians should consider it only when treatment is indicated and other methods cannot establish the diagnosis.

A cited five-year model estimated that a choroidal nevus converted to a malignant tumor at 1% with zero risk factors, 11% with one, 22% with two, 34% with three, 51% with four, and 55% with five. These are model estimates for groups with nevi, not a personal forecast.

Use tumor and patient details to choose among treatments

Treatment depends on the tumor’s size and location, visual potential, your preferences, and whether the cancer has spread. The goal is to control the tumor while considering eye preservation, useful vision, and your wider health needs.

Possible treatments include plaque radiation, proton or other charged-particle radiation, stereotactic radiation, local tumor removal, endoresection, and removal of the eye. Your specialist may also discuss observation when the diagnosis is not firmly established or when a small lesion needs monitoring for growth.

For a small tumor, the discussion may compare watching for growth with immediate treatment. If growth is documented, typically within six months of observation, definitive treatment is typically recommended. Observation may be acceptable for a posterior uveal tumor when the diagnosis is uncertain, particularly when the tumor is less than 2 to 2.5 mm in elevation and 10 mm in diameter.

Radiation is often considered for small and medium tumors. Plaque radiation is one treatment option for medium-sized choroidal melanomas. Eye removal is usually considered for larger or more advanced tumors, poor vision, recurrent tumors, and some multifocal or diffuse iris melanomas.

The choice is not based on tumor size alone. Ask about the measured height, diameter, and location; whether observation is reasonable; how each option may affect vision in both eyes; whether the evaluation shows spread; and what follow-up examinations or imaging will be needed.

Compare the practical tradeoffs of radiation and surgery

Radiation and surgery approach the tumor in different ways. The practical choice depends on the tumor and your visual needs rather than on a single treatment label.

Option When it may be considered What treatment involves Main discussion point
Plaque brachytherapy Small or medium tumors, including medium posterior tumors smaller than 10 mm in height and 15 mm in diameter A radioactive plaque is sewn onto the outside wall of the eye, usually for a few days, then removed It can treat the tumor while keeping the eye, but radiation-related effects on vision need discussion
Proton beam radiotherapy Tumors close to the optic nerve or very large tumors for which plaque placement may be less effective Usually 4 to 5 daily outpatient treatments For small or medium tumors, outcomes can generally be similar to plaque radiation, so tumor and patient factors guide the choice
Eye removal Larger or more advanced tumors, poor visual function, recurrent tumors, or selected iris melanomas The affected eye is removed The operation is considered when other approaches may not fit the tumor or visual situation

Radiation showed local success rates upwards of 95% in one review. The same report found that nearly 50% of people had vision of 20/200 or worse because of radiation-related retinal or optic-nerve damage. Local tumor control and useful vision are different outcomes, so ask about both.

The goals of treatment are to stop tumor growth, preserve the eye when possible, preserve vision when possible, and improve survival. For most small and medium-sized tumors, radiation is described as the recommended treatment in one patient education source, with plaque brachytherapy the most common radiation form used in the United States.

For small- or medium-sized tumors, plaque and proton therapy can generally achieve similar outcomes. That comparison does not establish that either option fits your tumor. Ask how location, size, distance from the optic nerve, and the condition of your other eye change the balance.

Infographic stat row showing radiation local success upwards of 95%, nearly 50% of people with vision of 20/200 or worse, and proton therapy usually finished after 4-5 daily outpatient treatments.
Treatment discussions should address both tumor control and vision.

Understand what shapes prognosis

Spread risk is assessed separately from local eye control, so treatment of the eye does not remove the need for continued medical follow-up.

Prognosis depends on several factors:

  • Tumor thickness, diameter, and location.
  • Whether the tumor involves the ciliary body or has spread.
  • Tumor-cell features seen on pathology.
  • Genetic findings, including chromosome changes.
  • Your age.

Uveal melanoma is staged with the American Joint Committee on Cancer 8th Edition Tumour-Node-Metastasis system for eye cancer. Staging gives clinicians a shared way to describe tumor extent, but your specialist combines stage with imaging, pathology, and genetic findings.

In a cohort of 8,033 people, the 10-year metastatic rate was 5% for a 1-mm-thick tumor, 10% for a 2-mm-thick tumor, and 30% for a 6-mm-thick tumor. These rates measure metastasis over 10 years in that cohort and should not be used as an individual survival estimate.

A systematic review found clinically evident metastatic disease at initial presentation in less than 1% of people. Longer follow-up in that review found metastases in 31% within 5 years, 45% within 15 years, and almost 50% within 25 years. The different time points show why ongoing surveillance matters, but they do not determine your outcome.

After a diagnosis, care may involve eye and medical oncology teams, continued dilated examinations and eye imaging, liver-function testing, chest imaging, and abdominal imaging. Ask which tests apply to your tumor and how often they should occur.

A bar chart shows 10-year metastatic rates by tumor thickness: 5% for a 1-mm-thick tumor, 10% for a 2-mm-thick tumor, and 30% for a 6-mm-thick tumor. The rates come from a cohort and are not an individual estimate.
In the cited cohort, thicker tumors were associated with higher 10-year metastatic rates.

Arrange qualified evaluation for a new eye finding

Contact a qualified eye-care professional promptly about a new or worsening eye finding, even when you have little or no pain. If in doubt, contact a qualified professional promptly. Arrange an examination if you notice new flashes, floaters, vision loss, worsening loss of part of your visual field, blurry vision, or a concerning finding already identified during another examination.

Keep routine dilated eye examinations as recommended. These examinations help detect this cancer and may help preserve vision, conserve the eye, and prevent death.

Do not use the absence of pain as a reason to dismiss a new visual change. This cancer may be silent, and some tumors are found during routine examination rather than because symptoms brought you in.

Before the visit, write down when the change began, whether it affects one or both eyes, and whether it is getting worse. Bring information about earlier eye examinations and any known nevus or retinal finding. Use the visit to ask what was seen, which tests are needed, and when the next examination should occur.

Do not use the measurements or symptom list here to diagnose yourself or choose treatment. Let a qualified eye-care professional interpret the finding.

Book your eye appointment

A focused visit at Northwest Eye in Minnetonka can give you a place to review a new or concerning eye finding, your symptom timeline, previous eye records, and questions about diagnosis, treatment choices, and follow-up.

A qualified eye-care professional decides what your finding means and which evaluation or treatment fits your situation.

Questions to ask about testing and a suspicious eye finding

What is the difference between choroidal melanoma and ocular melanoma?

Choroidal melanoma starts in pigmented cells in the choroid, while ocular melanoma is a broader term that may include melanoma in other parts of the eye. The uveal tract includes the choroid, iris, and ciliary body. Ask your eye specialist which exact location and tumor type applies to your finding.

Can choroidal melanoma be diagnosed without a biopsy?

Yes, clinicians may establish the diagnosis through a dilated eye examination and imaging such as ultrasound, OCT, photography, or angiography. Fine-needle aspiration is generally reserved for situations in which treatment is indicated and other methods cannot establish the diagnosis because the procedure can cause significant harm.

How do doctors tell a choroidal nevus from melanoma?

Doctors look for growth and features such as thickness, fluid beneath the retina, visual symptoms, orange pigment, ultrasound hollowness, and location near the optic disc. A nevus may need imaging follow-up for at least 1.5 years, and the schedule depends on its features and your overall eye findings.

What should I bring to an appointment for a suspicious eye finding?

Bring the date your symptoms began, whether one or both eyes are affected, and whether the change is worsening. Include information about earlier eye examinations and any known nevus or retinal finding. Ask what was seen, which tests are needed, whether monitoring is appropriate, and when follow-up should occur. If treatment is discussed, ask which facility would provide it, what anesthesia plan would apply, what follow-up is expected, and which insurance or cost questions to raise with the treating center and your insurer.


locations

Serving Our Community

With six locations throughout the Twin Cities metro area, Northwest Eye is among the largest eye care providers in the Midwest. Be Eye Wise and schedule a general eye exam or a specific service consultation today. We have optical  at the following offices:  Golden Valley, Minnetonka, Maple Grove, St. Anthony, and Wayzata, MN.

8501 Golden Valley Rd.,
Suite 100 & 200
Golden Valley, MN 55427
Additional Golden Valley Information
12501 Whitewater Drive, Suite 110
Minnetonka, MN 55343
Additional Minnetonka Clinic (Crosstown) Information
12000 Elm Creek Blvd N., Suite 100
Maple Grove, MN 55369
Additional Maple Grove Information
2601 39th Ave NE., Suite 1
St. Anthony, MN 55421
Additional St. Anthony Information
1903 E. Wayzata Blvd., Suite 110
Wayzata, MN 55391

Additional Wayzata Information
7125 Tamarack Rd, Suite 150,
Woodbury, MN 55125
Additional Woodbury Information
11091 Ulysses St NE., Suite 400
Blaine, MN 55434
Additional Blaine Surgery Center Information
9801 Dupont Ave S., Suite 100
Bloomington, MN 55431
Additional Bloomington Surgery Center Information
12501 Whitewater Drive
Suite 320
Minnetonka, MN 55343
Additional Crosstown Surgery Center Information
10709 Wayzata Blvd., Suites 100 & 120
Minnetonka, MN 55305
Additional Minnetonka Surgery Center Information